Official Title
A Randomized, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of Once Weekly Subcutaneous Injections of Pemziviptadil (PB1046), a Sustained-Release VIP (Vasoactive Intestinal Peptide) ANalogue, in Hospitalized COVID-19 Patients at HiGh Risk for Rapid Clinical Deterioration and ARDS (PB1046 VANGARD Study)
Brief Summary

This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical deterioration, acute respiratory distress syndrome (ARDS) and death. The study will enroll approximately 210 hospitalized COVID-19 patients who require urgent decision-making and treatment at approximately 20 centers in the United States.

Detailed Description

The study will consist of a Screening/Pre-treatment period, on-site randomization to study
treatment. On Day 0 (Visit 2) subjects who meet inclusion criteria and none of exclusion
criteria will receive a weekly subcutaneous injection that will continue once weekly until
hospital discharge or for a maximum of 4 weeks during hospitalization, whichever is shorter.

All subjects will be randomized to either a low control (10 mg), middle (40 mg), or high (100
mg) dose of active treatment. If subject is not discharged, they will continue to Day 7, 14,
21 treatments. Pemziviptadil (PB1046) is expected to improve the clinical outcomes of
hospitalized COVID-19 subjects with an earlier hospital discharge and improvement in
survival.

The duration of hospitalization for each subject will be determined by clinical status
independent of study procedures. The estimated duration of the study for each subject,
including screening, is approximately 35+7 days. The subjects may be involved up to 42 days.

Terminated
Acute Respiratory Distress Syndrome
Coronavirus
Hypoxic Respiratory Failure
Hypoxemic Respiratory Failure
Respiratory Complication
Respiratory Insufficiency
Cardiac Dysfunction
Pneumonia
Pulmonary Edema
Pulmonary Inflammation
Respiratory Failure
Cytokine Storm
COVID 19
SARS-CoV-2
Cardiac Event
Cardiac Complication
Cardiac Failure
Cardiac Infarct

Drug: Pemziviptadil (PB1046)

Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection

Drug: Low Dose (10 mg) Control

Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection (10 mg diluted in sodium chloride to match active drug volume)

Eligibility Criteria

Inclusion Criteria:

1. Written or witnessed verbal informed consent from patient or remote legal authorized
representative (LAR) or remote family member as permitted by governing local or
central Institutional Review Board (IRB)/independent Ethic Committee (IEC).

2. Male or female 18-85 years old hospitalized COVID-19 patients (positive local
SARS-CoV2 test)

3. Receiving oxygen (O2) by face mask or nasal cannula/prongs and/or with elevated
markers of cardiac injury or dysfunction (hsTnI or NT-proBNP) as assessed by local
testing

Exclusion Criteria:

Subjects will be excluded from the study if they meet any of the following criteria:

1. Patients considered unsalvageable or expected to expire within 24 hours

2. On mechanical ventilation or imminent need for mechanical ventilation expected in the
next 24 hours

3. Evidence of acute end-organ injury in 2 or more organ systems (not including cardiac
or pulmonary), such as, renal, hepatic, or CNS injury

4. Receiving another investigational therapy for treatment or prevention of
COVID-19-related hypoxemic respiratory failure or ARDS other than antiviral therapy

5. Systolic blood pressure (SBP) < 95 mmHg and/or diastolic blood pressure (DBP) < 50
mmHg or overt symptomatic hypotension during screening

6. Resting heart rate > 110 BPM (beats per minute) during screening

7. Severe chronic renal failure as measured by the estimated glomerular filtration rate
(eGFR) of < 30 mL/min/1.73m2 using the local laboratory calculation of eGFR.

8. Significant liver dysfunction as measured by any one of the following at screening:

- ALT (Alanine transaminase) > 3.0 times ULN (upper limit of normal)

- AST (Aspartate transaminase) > 3.0 times ULN

- Serum bilirubin ≥ 1.6 mg/dL

9. Any in-patient surgical procedure or hospitalization (defined as > 23 hours) within 30
days of subject screening except for prior hospitalization for COVID-19

10. Known hypersensitivity to study drug or any of the excipients of the drug formulation

11. Pregnant or lactating female subjects

12. Any other condition which, in the opinion of the Investigator, would place the subject
at increased risk or would preclude obtaining informed consent or confound the
objectives of study

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 85 Years
Countries
United States
Locations

Baptist Health Research Institute
Jacksonville, Florida, United States

Sarasota Memorial Hospital
Sarasota, Florida, United States

The University of Kansas Medical Center
Kansas City, Kansas, United States

Adventist Healthcare White Oak Medical Center
Silver Spring, Maryland, United States

PhaseBio Pharmaceuticals Inc.
NCT Number
Keywords
Acute Respiratory Distress Syndrome (ARDS)
Respiratory distress/failure
Covid
MeSH Terms
COVID-19
Pneumonia
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Respiratory Insufficiency
Acute Lung Injury
Pulmonary Edema
Cardiovascular Diseases
Heart Failure
Syndrome
Inflammation
Cytokine Release Syndrome
Clinical Deterioration
VIP-ELP fusion molecule PB1046